Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Arvinas presented Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, showing dose-dependent improvements in oculomotor function and correlations between LRRK2 reduction and improvements in biomarkers related to endolysosomal function, neuroinflammation, and synaptic integrity in Parkinson's disease patients. The findings support continued clinical evaluation of ARV-102 for neurodegenerative diseases associated with LRRK2 dysregulation.

Arvinas Says ARV-102 Shows Dose-Dependent Eye Movement Improvement In 24-Patient Phase 1 Parkinson's Trial Not Designed To Assess Efficacy

Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement Disorders

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.